MetaCap

Nanobiotix S.A. (NBTX) vs UroGen Pharma (URGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nanobiotix S.A. (NBTX) has outperformed UroGen Pharma (URGN) over the past year, gaining 26.6% versus a gain of 6.9%. Over five years, NBTX leads with a +214.0% price change compared with +127.8% for URGN. UroGen Pharma is the larger company by market cap ($1.36 billion vs $1.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NBTX+26.61%URGN+6.88%
+173%+64%-44%
Nov 21, 20251 yearNov 20, 2026
NBTX+185.87%URGN+129.27%
+482%+189%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NBTX versus URGN key metrics
MetricNBTXURGN
Share price$26.50$27.65
Market cap$1.35B$1.36B
1-day change-2.98%-12.86%
YTD return+14.62%+18.06%
1-year return+26.61%+6.88%
5-year return+213.98%+127.76%
Forward P/E—11.08
EPS (TTM)$-1.27$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$109.79M
Revenue growth (YoY)—+21.45%
Net income (latest FY)—$-153.49M
Gross margin—88.66%
Operating margin—-113.73%
Net margin—-139.81%
52-week high$57.14$50.81
52-week low$19.14$16.50
Distance from 52-week high-53.62%-45.58%
Analyst consensusnonestrong_buy
Avg. price target upside+101.06%+119.57%
Average volume148.94K1.11M
Shares outstanding50.95M49.05M
Employees98300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NBTX has outperformed URGN by 19.7 percentage points over the past year.

About Nanobiotix S.A.

NBTX stock →

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About UroGen Pharma

URGN stock →

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees

NBTX vs URGN FAQ

Which is bigger, Nanobiotix S.A. or UroGen Pharma?

UroGen Pharma (URGN) is larger, with a market capitalization of $1.36B compared with $1.35B for Nanobiotix S.A. (NBTX).

Which stock has performed better over the past year, NBTX or URGN?

NBTX returned +26.61% over the past 12 months, compared with +6.88% for URGN (price return, excluding dividends). Past performance does not predict future results.

Are Nanobiotix S.A. and UroGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons